New 2022 ADA/EASD guidelines: GLPP-1 RA/Insulin combination is recommended
![](/.imaging/webp/sanofi-templates/article-hero-w768/dam/campus-sanofi-qa/Article-Images/science-hero-(2)-(1).jpg7/jcr:content/science%20hero%20(2)%20(1).jpg)
ADA/EASD recommend considering combination injectables therapy of basal insulin/GLP-1 RA (Such as Soliqua®) as valuable treatment option to provide adequate efficacy for achieving and maintaining glycemic goals.
![](/dam/jcr:33f3fbff-27dd-4e60-b177-f09263071387/Soliqua-MVA-AMERICAN-DIABETES-ASSOCIATION_03.webp)
![](/dam/jcr:af4b15d0-02db-4c94-963c-2f432b4764de/Soliqua-MVA-AMERICAN-DIABETES-ASSOCIATION_02.webp)
Reference
- American Diabetes Association. Diabetes Care 2023;46(Suppl. 1):S140–S157 | https://doi.org/10.2337/dc23-S009.
Related articles
MAT-BH-2300161/v1/March 2023